Vivera Appoints Dr. Guido Jouret as Interim Chief Technology Officer
NEWPORT BEACH, Calif. — Vivera is pleased to announce the appointment of Guido Jouret, Ph.D., to the Company’s Board of Advisors as Senior Technology Advisor and Interim Chief Technology Officer. In preparation for Vivera’s next phase of growth and development, focused on science, medical, and technology-driven products, the Company has strategized to establish a strong Technology […]
Vivera Welcomes Two Veteran Advisors to Its Technology Board
NEWPORT BEACH, Calif. — Vivera is pleased to welcome two Advisors to the Company’s Technology Advisory Board, Mr. Robert Massoudi and Mr. Bryan Hughes. Mr. Massoudi and Mr. Hughes will support Vivera in its product and software development initiatives, and forge strategic partnerships for ZICOH, the Company’s high-tech, electronic, dose-controlled medication delivery system designed to […]
Vivera Appoints Dr. Fabio Macciardi as Neurogenetics Scientific Advisor
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals is pleased to welcome Fabio Macciardi, M.D., Ph.D., to its Advisory Board as Neurogenetics Scientific Advisor to the Company’s Biosciences Division. As an expert in neurogenetics, Dr. Macciardi will assist Vivera in the research and development of targeted genetic therapies to address the unmet needs of patients with various central nervous […]
Vivera Receives 3rd U.S. Patent Allowance for ZICOH Drug Delivery Device
NEWPORT BEACH, Calif.— Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH, the Company’s high-tech, electronic dose-controlled portfolio of drug delivery devices. The patent allowance from the U.S. Patent and Trademark Office (USPTO) secures ZICOH’s rights as a smart dosing system with automated delivery, measurement, and management for oral format […]
Vivera Partners with NINDS of NIH to Identify Potential Stuttering Treatments
Vivera Executes Letter of Intent to Enter a Cooperative Research and Development Agreement with the NINDS of NIH to Assess Therapeutic Agents for Potential Treatments of Stuttering Disorders NEWPORT BEACH, Calif.—Vivera Biosciences, a division of Vivera Pharmaceuticals dedicated to the research and development of innovative medical technologies and pharmaceutical therapies, is pleased to announce its […]
Vivera Enters $23 Billion Telehealth Industry with Patent Allowance for MDZone
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985 entitled, “Self-Contained, Portable, Sanitization Device and Telemedicine Station,” for the Company’s MDZone platform from the United States Patent and Trademark Office (USPTO). This Notice of Allowance indicates that the patent […]
Will Recent $32 Billion in Opioid Settlements Prevent Addiction? Vivera Has the Answer.
NEWPORT BEACH, Calif.— As large corporations are being held responsible for fueling the opioid crisis, an estimated $32 billion in settlements are being allocated to pay states, Native American tribes, victim families, and current patients struggling with addiction. While a majority of the payouts will allegedly go to “reducing future addiction and death,” it is […]
Vivera Engages Star Legal Team to Lead $500 Million Lawsuit Against USA Today
NEWPORT BEACH, Calif.— Vivera Pharmaceuticals, Inc. today announced the appointment of leading corporate law firm, Byrd Campbell, P.A., to represent the Company in its defamation lawsuit against USA Today and its parent companies, Gannett Co., Inc. and Gannett Satellite Information Network, LLC (“Gannett”). In June 2021, USA Today published a defaming article about Vivera and […]
Vivera Pharmaceuticals Issues Statement Regarding LuSys Laboratories Covid-19 Tests
Vivera Pharmaceuticals is highly discouraged to read the latest FDA safety communication that erroneously lists Vivera Pharmaceuticals as a brand of LuSys Laboratories or as a distributor of the LuSys Eagle Diagnostics test. While Vivera did work with LuSys Laboratories in mid-2020, the scope of that engagement was limited to development of a United States […]
Vivera Appoints Donald D’Ambrosio as Chief Financial Officer
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals announced today, the appointment of Donald D’Ambrosio as the Company’s Chief Financial Officer (CFO). With over four decades of experience serving in executive and officer roles within banking, investment, and finance firms, Mr. D’Ambrosio will direct and oversee the Company’s financial activities. He will navigate transactions, manage risk, and work with external regulatory agencies related to […]
